Ranbaxy, Takeda Strike Licensing Deal Over Actos

By Samuel Howard

Law360, New York (March 15, 2010, 1:45 PM ET) -- Ranbaxy Laboratories Ltd. has agreed to license Takeda Pharmaceutical Co. Ltd.'s Actos patents in order to end a protracted legal battle and bring a generic version of the blockbuster diabetes treatment to market.

India-based Ranbaxy announced Monday that Takeda had agreed to drop its infringement action in the U.S. District Court for the Southern District of New York and grant Ranbaxy a nonexclusive royalty-free license to the seven U.S. patents covering Actos, the brand name for pioglitazone hydrochloride.

Under the terms of the deal, Ranbaxy is...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles